REYKJAVIK, Iceland, May 3, 2007 (PRIME NEWSWIRE) -- Actavis Group (OMX:ACT) announces that it has withdrawn its interest to acquire the generics division of Merck KGaA. Actavis has performed extensive due diligence on the division and identified significant potential synergies with Actavis operations. However, the Board of Actavis considers that at the price levels that Actavis understands are being offered for the division by other bidders, the transaction would not produce value for Actavis’ shareholders and therefore to proceed to the next stage of the bidding process would not be in their best interests.
